Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
LOS ANGELES--(BUSINESS WIRE)---- $SRPT #SRPT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc.
Sarepta Therapeutics: Bombs Away
12:29am, Tuesday, 12'th Jan 2021
The biotech space remains one of my favorite sectors for outsized gains. With the potential for large gains needs to be balanced with far more volatility than seen in other sectors.
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
12:34pm, Monday, 11'th Jan 2021
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
Here's Why Sarepta Therapeutics Lost Support on Wall Street
07:56am, Sunday, 10'th Jan 2021
Disappointing trial results caused a flock of analysts to drop their ratings on this biotech stock.
NEW YORK, Jan. 9, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, I
LOS ANGELES--(BUSINESS WIRE)---- $SRPT #SRPT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc.
SRPT EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc. – SRPT
01:35pm, Friday, 08'th Jan 2021
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ:
Why Tenet, CVS, Thermo Fisher And Sarepta Are Moving Today
12:54pm, Friday, 08'th Jan 2021
Tenet Healthcare (NYSE: THC) shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $27 to $60. Tenet is a Dallas-based healthcare provider orga
SRPT Stock Alert: Why Sarepta Therapeutics Stock Is Plunging Today
11:26am, Friday, 08'th Jan 2021
Shares of SRPT stock are getting hammered on Friday after Sarepta Therapeutics reported negative results from a treatment trial. The post SRPT Stock Alert: Why Sarepta Therapeutics Stock Is Plunging T
Serepta Stock Nearly Halves After Failed Gene Therapy Study
10:07am, Friday, 08'th Jan 2021
The shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have nearly halved this morning, down 49.8% at $84.90 at last check, after the company's experimental gene therapy to treat Duchene muscular dystro
Sarepta (SRPT) Down on Unsatisfactory Data for DMD Candidate
09:47am, Friday, 08'th Jan 2021
Sarepta (SRPT) posts top-line results from part 1 of Study 102, evaluating a single dose of its gene therapy candidate SRP-9001 for treating DMD. Shares fall.
Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint
08:50am, Friday, 08'th Jan 2021
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new year, are sinking. What Happened: Cambridge,
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
08:30am, Friday, 08'th Jan 2021
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pr
Sarepta stock plunges more than 50% after mixed results from drug study
05:13pm, Thursday, 07'th Jan 2021
Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.
-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- -- SRP-9
